Tender

Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

NHS ENGLAND

This public procurement record has 1 release in its history.

Tender

04 Jun 2026 at 15:37

Summary of the contracting process

NHS England has initiated a tender process for the provision of gene replacement therapy services focused on spinal muscular atrophy (SMA), titled "Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service". This procurement falls under the health services category (CPV 85100000) and covers the UK region. The process has been structured into lots, allowing bidders to apply based on their capability, with a submission deadline set for 8 July 2026. The procurement is currently in the tender stage, following an open procedure, and seeks to serve the population under NHS England, with potential contract durations extending up to five years.

This tender offers significant opportunities for businesses operating within the healthcare services industry, particularly those specialising in gene therapy and rare genetic disorders. Suppliers capable of providing innovative solutions and tailored therapeutic services for SMA are well-suited to compete. Engaging in this procurement process can enable companies to expand their influence in the health sector, leveraging cutting-edge medical therapies to deliver impactful patient outcomes. By strategically aligning with NHS England's objectives, businesses can enhance their portfolio and contribute to advancing healthcare services for those affected by SMA.

Find more tenders on our Open Data Platform.
How relevant is this notice?

Notice Title

Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Notice Description

Onasemnogene abeparvovec intravenous (Zolgensma(r)) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE's technology appraisal programme, with an expected final guidance publication date in late 2026.

Lot Information

Lot 1

Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)

Options: Contract period for 3 years with the option to extend up to 2 additional years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Lot 2

Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)

Options: Contract period for 3 years with the option to extend up to a further 2 years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Lots 3

Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)

Options: Contract period for 3 years with the option to extend up to a further 2 years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-06ae08
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/053026-2026
Current Stage
Tender
All Stages
Tender

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services


CPV Codes

85100000 - Health services

Notice Value(s)

Tender Value
£26,136,000 £10M-£100M
Lots Value
£26,136,000 £10M-£100M
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
4 Jun 20261 weeks ago
Submission Deadline
8 Jul 20264 weeks to go
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Active
Lots Status
Active
Awards Status
Not Specified
Contracts Status
Not Specified

Contracting Authority (Buyer)

Main Buyer
NHS ENGLAND
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Post Town
South East London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
Not specified

Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-06ae08-2026-06-04T16:37:40+01:00",
    "date": "2026-06-04T16:37:40+01:00",
    "ocid": "ocds-h6vhtk-06ae08",
    "description": "Spinal muscular atrophy (SMA) is a rare genetic disorder that causes muscle weakness and progressive loss of movement. The severity of SMA can vary greatly between individuals. Historically, the condition has been classified into different types, determined by clinicians at the time of diagnosis. This classification is based on both the age at which symptoms first appear, and the highest level of motor function achieved by the patient. <br/><br/>The types range from type 0, the most severe form, where symptoms are present before birth and most affected infants do not survive past 6 months, through to type 4, which develops in adulthood and is associated with mild motor impairment and a normal life span. However, because the disease presents so variably, consistently categorising patients into these types at the point of diagnosis can be challenging. <br/><br/>Onasemnogene abeparvovec intravenous (Zolgensma(r)) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE's technology appraisal programme, with an expected final guidance publication date in late 2026. <br/><br/>This procurement is based on Lots with the intention to cover the population served by NHS England.<br/><br/>The objective is to allow Bidders to apply for different Lots that align best with their service capability and capacity.<br/><br/>Lots:<br/>Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)<br/><br/>Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)<br/><br/>Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)<br/><br/><br/><br/><br/>To express interest and participate in the Competitive Process, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:<br/><br/>Phone: 08000988201<br/>E-mail: support-health@atamis.co.uk<br/><br/>The closing date for completed Competitive Process responses is 12:00pm (noon), on Wednesday 8 July 2026.<br/><br/>Atamis Project reference C449537.<br/><br/>The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to<br/>the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.",
    "initiationType": "tender",
    "tender": {
        "id": "ocds-h6vhtk-06ae08",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service",
        "status": "active",
        "classification": {
            "scheme": "CPV",
            "id": "85100000",
            "description": "Health services"
        },
        "mainProcurementCategory": "services",
        "description": "Onasemnogene abeparvovec intravenous (Zolgensma(r)) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE's technology appraisal programme, with an expected final guidance publication date in late 2026.",
        "value": {
            "amount": 26136000,
            "currency": "GBP"
        },
        "lots": [
            {
                "id": "0",
                "title": "Lot 1",
                "description": "Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)",
                "value": {
                    "amount": 8527000,
                    "currency": "GBP"
                },
                "contractPeriod": {
                    "durationInDays": 1800
                },
                "hasRenewal": true,
                "renewal": {
                    "description": "Commissioners may decide to to renew the contract at the end of its term"
                },
                "submissionTerms": {
                    "variantPolicy": "notAllowed"
                },
                "hasOptions": true,
                "options": {
                    "description": "Contract period for 3 years with the option to extend up to 2 additional years"
                },
                "status": "active"
            },
            {
                "id": "3",
                "title": "Lot 2",
                "description": "Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)",
                "value": {
                    "amount": 8283000,
                    "currency": "GBP"
                },
                "contractPeriod": {
                    "durationInDays": 1800
                },
                "hasRenewal": true,
                "renewal": {
                    "description": "Commissioners may decide to to renew the contract at the end of its term"
                },
                "submissionTerms": {
                    "variantPolicy": "notAllowed"
                },
                "hasOptions": true,
                "options": {
                    "description": "Contract period for 3 years with the option to extend up to a further 2 years"
                },
                "status": "active"
            },
            {
                "id": "1 and 2",
                "title": "Lots 3",
                "description": "Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)",
                "value": {
                    "amount": 9326000,
                    "currency": "GBP"
                },
                "contractPeriod": {
                    "durationInDays": 1800
                },
                "hasRenewal": true,
                "renewal": {
                    "description": "Commissioners may decide to to renew the contract at the end of its term"
                },
                "submissionTerms": {
                    "variantPolicy": "notAllowed"
                },
                "hasOptions": true,
                "options": {
                    "description": "Contract period for 3 years with the option to extend up to a further 2 years"
                },
                "status": "active"
            }
        ],
        "items": [
            {
                "id": "0",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "0"
            },
            {
                "id": "3",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "3"
            },
            {
                "id": "1 and 2",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1 and 2"
            }
        ],
        "submissionMethod": [
            "electronicSubmission",
            "written"
        ],
        "submissionMethodDetails": "https://atamis-1928.my.site.com/s/Welcome",
        "communication": {
            "atypicalToolUrl": "https://atamis-1928.my.site.com/s/Welcome"
        },
        "procurementMethod": "open",
        "procurementMethodDetails": "Open procedure",
        "coveredBy": [
            "GPA"
        ],
        "tenderPeriod": {
            "endDate": "2026-07-08T12:00:00+01:00"
        },
        "submissionTerms": {
            "languages": [
                "en"
            ],
            "bidValidityPeriod": {
                "durationInDays": 180
            }
        },
        "awardPeriod": {
            "startDate": "2026-07-08T13:00:00+01:00"
        },
        "bidOpening": {
            "date": "2026-07-08T13:00:00+01:00"
        },
        "hasRecurrence": true
    },
    "parties": [
        {
            "id": "GB-FTS-130973",
            "name": "NHS England",
            "identifier": {
                "legalName": "NHS England"
            },
            "address": {
                "streetAddress": "Wellington House, 133-135 Waterloo Rd",
                "locality": "London",
                "region": "UKI",
                "postalCode": "SE1 8UG",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Surinder Kahlon",
                "email": "surinder.kahlon@nhs.net",
                "url": "https://atamis-1928.my.site.com/s/Welcome"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.england.nhs.uk/",
                "buyerProfile": "https://www.england.nhs.uk/",
                "classifications": [
                    {
                        "id": "BODY_PUBLIC",
                        "scheme": "TED_CA_TYPE",
                        "description": "Body governed by public law"
                    },
                    {
                        "id": "07",
                        "scheme": "COFOG",
                        "description": "Health"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-141301",
            "name": "NHS Arden and Greater East Midlands Commissioning Support Unit",
            "identifier": {
                "legalName": "NHS Arden and Greater East Midlands Commissioning Support Unit"
            },
            "address": {
                "streetAddress": "Cardinal Square, 10 Nottingham Road",
                "locality": "Derby",
                "postalCode": "DE1 3QT",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ],
            "details": {
                "url": "https://www.ardengemcsu.nhs.uk/"
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-130973",
        "name": "NHS England"
    },
    "language": "en"
}